

**LISTING OF THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 7. (Cancelled)

8. (Currently Amended) A method of identifying a candidate therapeutic agent for a tuberous sclerosis complex associated disorder, the method comprising;

- (a) providing a test cell population comprising a cell capable of expressing ~~one or more the~~ nucleic acid ~~sequences selected from the group consisting~~ sequence of TSC ~~122-1-8, 10-12, 15-141 and 142~~;
- (b) contacting the test cell population with a test agent;
- (c) measuring expression of ~~one or more of the~~ nucleic acid ~~sequences~~ sequence in the test cell population;
- (d) comparing the expression of the gene in the test cell population to the expression of the nucleic acid ~~sequences~~ sequence in a reference cell population comprising at least one cell whose tuberous sclerosis status is known; and
- (e) identifying a difference in expression levels of the nucleic acid ~~sequences, if present,~~ sequence in the test cell population and reference cell population, thereby identifying a therapeutic agent for a tuberous sclerosis complex associated disorder.

9. (Currently Amended) A method of identifying an individualized therapeutic agent suitable for treating a tuberous sclerosis complex associated disorder appropriate in a selected subject, the method comprising:

- (a) providing from the subject a test cell population comprising cells capable of expressing ~~one or more the~~ nucleic acid ~~sequences selected from the group consisting~~ sequence of TSC ~~122-1-8, 10-12, 15-141 and 142~~;
- (b) contacting the test cell population with the therapeutic agent;
- (c) measuring expression of ~~one or more of the~~ nucleic acid ~~sequences~~ sequence in the test cell population;

- (d) comparing the expression of the nucleic acid sequences in the test cell population to the expression of the nucleic acid ~~sequences~~ sequence in a reference cell population comprising at least one cell whose tuberous sclerosis complex associated disorder status is known; and
- (e) identifying a difference in expression levels of the nucleic acid ~~sequences, if present,~~ sequence in the test cell population and reference cell population, thereby identifying a therapeutic agent appropriate for the subject.

10. – 19. (Cancelled)

20. (New) A method of identifying a candidate therapeutic agent for a tuberous sclerosis complex associated disorder, the method comprising;

- (a) providing a polypeptide encoded by a nucleic acid sequence comprising TSC 122;
  - (b) screening for an agent that binds to the polypeptide;
- thereby identifying a therapeutic agent for a tuberous sclerosis complex associated disorder.

21. (New) The method of claim 20, wherein the agent is an antibody.

22. (New) The method of claim 20, wherein the tuberous sclerosis complex associated disorder is renal cell carcinoma.

23. (New) The method of claim 20, wherein the therapeutic agent is further screened for a biological effect on a tuberous sclerosis complex associated disorder selected from the group consisting of: inhibition of tumor growth, inhibition of matrix invasion and inhibition of metastatic dissemination.